Windy City Media Group Frontpage News

THE VOICE OF CHICAGO'S GAY, LESBIAN, BI, TRANS AND QUEER COMMUNITY SINCE 1985

home search facebook twitter join
Gay News Sponsor Windy City Times 2022-03-16
DOWNLOAD ISSUE
Donate

Sponsor
Sponsor
Sponsor

  WINDY CITY TIMES

PrEP options likely to change following Truvada patent expiration
by Matt Simonette
2021-03-04

This article shared 2323 times since Thu Mar 4, 2021
facebook twitter pin it google +1 reddit email


Among the myriad challenges facing HIV/AIDS advocates and healthcare providers has been increasing use of pre-exposure prophylaxis, or PrEP, among persons at risk for HIV transmission. A PrEP intervention, which usually consists of taking the oral medication Truvada, has been shown to decrease the risk of transmission by more than 90 percent.

Truvada was approved for PrEP use by the Food and Drug Administration in 2012 and, since then, has been widely prescribed by physicians to help at-risk patients prevent HIV transmission (it was earlier used to treat persons living with HIV). But Truvada's patent expiration in 2020 means both generic options for consumers are forthcoming and that a competing drug, Descovy, by the same manufacturer, is already on the market.

Some advocates are looking forward to having lower-cost options available. AIDS Foundation of Chicago (AFC) Senior Director of Prevention Advocacy and Gay Men's Health Jim Pickett suspects that "lower drug costs will lower the cost of access and alleviate some pressure on the system."

He added, "With PrEP, the costs are not just about the drug. There are costs affiliated with seeing your doctor, having blood work done, being tested for HIV and STI's. It's important to remember that services that come along with PrEP are part of the program—PrEP isn't just a prescription. If our system can spend less on the drug, there's arguably more money to cover those other things which can be prohibitive for people."

The cost of Truvada—which is a combination of the drugs known generically as tenofovir disoproxil fumarate and emtricitabine—has indeed been a key deterrent to widespread PrEP implementation. A month's supply of the medication is often $1,500-2,000. Nevertheless, many insurers cover Truvada in their formularies, and the medication's manufacturer, Foster City, California-based Gilead Sciences, provides consumer assistance for monthly co-payments their plans require.

Various public health agencies have also made PrEP access a central component to long-term strategies that eliminate new HIV transmissions, such as the Getting to Zero initiative launched in Illinois in late 2018. The federal government announced a similar program with PrEP interventions playing a central role in early 2019.

Nevertheless, PrEP adoption numbers remain far behind where advocates and providers want to see them. Getting the message about PrEP to white gay men has been a relatively minimal challenge, but communicating that same message to diverse audiences at risk, such as transgender women or young Black men, remains problematic. Usage in the southern United States, where a large number of new HIV transmissions take place, is also low.

In late 2019, Gilead announced it would donate a five-year supply of Truvada to 200,000 people. Their Truvada patent expired in late 2020. The company reached an exclusivity agreement for six months Israeli pharmaceutical manufacturer Teva for a generic version of tenofovir disoproxil fumarate and emtricitabine. Starting in spring 2021, Teva's exclusivity window expires and any manufacturer can produce a generic version of tenofovir disoproxil fumarate and emtricitabine.

Gilead still intends to remain a player in manufacturing and distributing medications for PrEP, however. In 2019, it received approval for use of Descovy as a PrEP intervention and has aggressively marketed the new drug as a replacement for Truvada. Google users who search "Truvada generic" will likely spot an advertisement for Descovy toward the top of their results.

Among the advantages of Descovy, according to Gilead, are reduced chances of complications to kidneys or bone density, which are stated side-effects to Truvada. But Descovy shares the same high cost as Truvada, about $16,600-20,000 a year, according to aidsmap.com .

Many advocates and providers say that there is no need for a "mass exodus" from Truvada to Descovy for PrEP users, Pickett said.

"In terms of prescribing for PrEP, the vast majority of people using Truvada for PrEP have absolutely zero clinical need to switch over to Descovy," he added. "The only clinical reason to switch would be if you have some underlying kidney or bone disease, or if Truvada is giving your kidneys a hard time."

Gilead could not provide a spokesperson to comment on Descovy by this article's deadline. Shortly after Descovy was approved for PrEP in October 2019, Daniel O'Day, Gilead's chairman and CEO, said the new medication nevertheless "provides a new HIV prevention option that matches Truvada's high efficacy with statistically significant improvements in renal and bone safety, which can be an important consideration as people at risk increasingly use PrEP for longer periods of time."

Prior to her appointment as director of the Centers for Disease Control and Prevention, Rochelle Walensky, MD, was lead author on a March 2020 Annals of Internal Medicine study which concluded that mitigating for Truvada's side-effects with a new medication was outweighed by the benefits of a lower-cost generic substitute for Truvada. Other researchers also have expressed concern that Descovy has not been tested on as diverse a population as Truvada has been.

"We already are seeing insurance companies pointing people to the generic alternative—when you are prescribed PrEP, the insurance company might cover the generic form of Truvada," Pickett said. "They may or may not be inclined to cover Truvada itself. We are also seeing insurance companies put in utilization-management for Descovy, so if you are prescribed Descovy, the doctor has to show clinical need."

Gilead has also been involved in extensive litigation with the federal government regarding the PrEP-related patents. The CDC sued the company in 2019, maintaining that it had not been properly compensated for federal researchers' contributions to Truvada and Descovy's development. In January 2021, a federal judge rejected the Justice Department's motion to dismiss Gilead's counterclaims that the federal government had been in breach of key contracts, so the litigation will continue.

But for now, a key challenge for stakeholders remains getting the costs under control. Using PrEP represents a collective commitment of time and money for patients, providers and insurers.

In the years ahead, the PrEP landscape will likely change even further. An injectable version of the intervention has proven to be as effective as oral applications. In such a scenario, the medication cabotegravir could be injected and offer two months' worth of protection for patients who don't wish to take a pill every day.

Pickett said he didn't foresee injectable PrEP completely replacing pills however, noting that compliance challenges might only shift for some consumers. While the injection saves the patient from the responsibility of taking a pill, they'd still need a bimonthly appointment to receive it.

"I don't see it as replacing [oral medication]—I see it as being additive," Pickett said. "I see it drawing in people who struggle with PrEP because it is a pill, or aren't interested because it's a pill. Overall, if we do it right and create support systems that make it easy for people to get their shots—imagine being able to do it at Walgreens—I'll be super-excited about it. It means people having more options and more protection."


This article shared 2323 times since Thu Mar 4, 2021
facebook twitter pin it google +1 reddit email

  ARTICLES YOU MIGHT LIKE

Gay News

CDC publishes new HIV surveillance reports 2022-05-24
- The Centers for Disease Control and Prevention (CDC) published a new HIV surveillance report: Diagnoses of HIV Infection in the United States and Dependent Areas, 2020; and a new HIV supplemental surveillance report: Monitoring Selected National ...


Gay News

HIV/AIDS activist Rae Lewis-Thornton on her new memoir, 'Unprotected' 2022-05-18
- Emmy-winning HIV/AIDS activist, author, minister, political organizer, motivational speaker, life coach, jewelry designer and social media figure Rae Clara Lewis-Thornton's recently released book, Unprotected: A Memoir, is already a pre-release ...


Gay News

PASSAGES Dr. David Ostrow dies at 74 2022-05-14
- Longtime researcher Dr. David Gene Ostrow, of Chicago, died unexpectedly on Feb. 16 at home. He was 74. The cause of death was end-stage renal disease, according to the Tribute Archive website. Ostrow was born on ...


Gay News

Running squad 'Team to End AIDS' calls for participants to raise funds 2022-05-10
-- From a press release - (Chicago, IL) Over the last 19 years, TEAM TO ENDS AIDS (T2)—the only HIV charity fundraising marathon team in the Midwest—has raised more than $13 million for HIV/AIDS awareness and direct support for those living with ...


Gay News

Book-signing for HIV/AIDS activist's 'Unprotected: A Memoir' on May 21 2022-05-05
-- From a press release - "I had been torn apart by the doings of others and blamed myself for surviving to the best of my ability. It would literally take decades for me to understand that I was the product of what happened to me." Emmy ...


Gay News

NATIONAL Campus Pride, HIV and the military, IVF suit, Billie Jean King 2022-05-01
- Campus Pride—along with 36 other national/regional organizations such as GLSEN, PFLAG National and TransAthlete.com—requested that the National Center for Education Statistics (NCES) incorporate non-binary students into ...


Gay News

Indiana Univ. to host inaugural national HIV conference 2022-04-26
- Indiana University (IU) will host the first IU National HIV Conference, "Stepping into the 5th Decade: Evolving Our Response to HIV," June 8-11 in Indianapolis. Hosted by the Office of the Vice President for Diversity, Equity ...


Gay News

'It Was Vulgar and It Was Beautiful' explores art collective's part in HIV/AIDS activism 2022-04-23
- In Jack Lowery's book, It Was Vulgar and It Was Beautiful: How AIDS Activists Used Art to Fight a Pandemic, the historian shares how the art collective Gran Fury utilized community-made propaganda to address the HIV/AIDS ...


Gay News

Federal court strikes down Pentagon's restrictions on military service of people Living with HIV as unconstitutional 2022-04-07
-- From a press release - "The court ruled that the Pentagon's policies regarding service members with HIV are not only outdated, but unlawful, arbitrary and capricious, and unconstitutional . . . one of the strongest judicial rulings in over two decades ...


Gay News

Simmons measure passes Senate, would allow pharmacists to provide HIV testing, PrEP and PEP medications 2022-04-01
-- From a press release - SPRINGFIELD — To allow more people to access HIV preventative care easier, Illinois state Sen. Mike Simmons (D-Chicago) is leading a measure to allow pharmacists to provide HIV tests and preventative medications to help reduce new ...


Gay News

AFC calls on state legislature to pass Getting to Zero Illinois 2030 bills 2022-03-31
- AIDS Foundation Chicago (AFC) held its annual HIV Advocacy Day on March 9, saying it is focused on the Getting to Zero Illinois Plan (GTZ-IL) that aims to end the HIV epidemic in the state by ...


Gay News

San Francisco to host largest display of AIDS Memorial Quilt in a decade 2022-03-29
- The National AIDS Memorial will mark the 35th anniversary of the AIDS Memorial Quilt with an historic outdoor display in Golden Gate Park that will feature nearly 3,000 hand-stitched panels of the Quilt. The free public ...


Gay News

Elton John AIDS Foundation Academy Awards Viewing Party raises $8.6M 2022-03-28
- The 30th annual Elton John AIDS Foundation Academy Awards Viewing Party took place March 27 at West Hollywood Park, raising $8.6 million for the foundation's work to end AIDS. The event was hosted by 12-time Grammy-winning ...


Gay News

Legislation introduced to increase critical access to HIV prevention medications 2022-03-04
-- Press release from the Office of State Representative Kelly M. Cassidy 14th District - SPRINGFIELD Yesterday evening, HB4430 Increased Access to PrEP and PEP sponsored by Rep. Kelly M. Cassidy was brought to the Illinois House floor to continue to address the health disparities communities ...


Gay News

Lady Gaga, Billy Porter, Eric McCormack to co-host 30th Elton John AIDS Foundation Oscars Viewing Party 2022-03-02
- Elton John AIDS Foundation announced Academy Award and 12-time Grammy-winning singer/songwriter/actress Lady Gaga; Emmy, Tony and Grammy winner Billy Porter; and Emmy-winning actor Eric McCormack (Will & Grace) are set ...


 



Copyright © 2022 Windy City Media Group. All rights reserved.
Reprint by permission only. PDFs for back issues are downloadable from
our online archives. Single copies of back issues in print form are
available for $4 per issue, older than one month for $6 if available,
by check to the mailing address listed below.

Return postage must accompany all manuscripts, drawings, and
photographs submitted if they are to be returned, and no
responsibility may be assumed for unsolicited materials.
All rights to letters, art and photos sent to Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago
Gay and Lesbian News and Feature Publication) will be treated
as unconditionally assigned for publication purposes and as such,
subject to editing and comment. The opinions expressed by the
columnists, cartoonists, letter writers, and commentators are
their own and do not necessarily reflect the position of Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago Gay,
Lesbian, Bisexual and Transegender News and Feature Publication).

The appearance of a name, image or photo of a person or group in
Nightspots (Chicago GLBT Nightlife News) and Windy City Times
(a Chicago Gay, Lesbian, Bisexual and Transgender News and Feature
Publication) does not indicate the sexual orientation of such
individuals or groups. While we encourage readers to support the
advertisers who make this newspaper possible, Nightspots (Chicago
GLBT Nightlife News) and Windy City Times (a Chicago Gay, Lesbian
News and Feature Publication) cannot accept responsibility for
any advertising claims or promotions.

 
 

TRENDINGBREAKINGPHOTOS







Sponsor
Sponsor
Sponsor


 



Donate


About WCMG      Contact Us      Online Front  Page      Windy City  Times      Nightspots
Identity      BLACKlines      En La Vida      Archives      Advanced Search     
Windy City Queercast      Queercast Archives     
Press  Releases      Join WCMG  Email List      Email Blast      Blogs     
Upcoming Events      Todays Events      Ongoing Events      Bar Guide      Community Groups      In Memoriam     
Privacy Policy     

Windy City Media Group publishes Windy City Times,
The Bi-Weekly Voice of the Gay, Lesbian, Bisexual and Trans Community.
5315 N. Clark St. #192, Chicago, IL 60640-2113 • PH (773) 871-7610 • FAX (773) 871-7609.